Welcome to our dedicated page for Castle Biosciences SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Castle Biosciences, Inc. (CSTL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed issuer. Castle Biosciences files reports with the U.S. Securities and Exchange Commission that cover its financial performance, governance changes, risk factors and material events related to its molecular diagnostics business in dermatologic and gastroenterological disease.
Investors can review current reports on Form 8-K, where Castle discloses items such as quarterly financial results, updated revenue guidance, the release of investor presentations and amendments to its bylaws. For example, 8-K filings describe when the company announces earnings for periods such as the quarter ended September 30, 2025, or when its board adopts amended and restated bylaws addressing stockholder meetings, director nominations, voting standards and indemnification provisions.
Alongside 8-Ks, users can access annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the SEC feed). These filings typically contain audited or reviewed financial statements, management’s discussion and analysis of results, details on Castle’s test portfolio, information about markets served and disclosures about risks associated with its diagnostics operations.
For those monitoring governance and capital structure, the SEC filings also identify Castle Biosciences’ state of incorporation (Delaware), the class of securities registered (common stock, $0.001 par value per share) and its listing on The Nasdaq Global Market under the symbol CSTL.
Stock Titan enhances this raw filing data with AI-powered summaries that explain key points in accessible language. Users can quickly see the main themes of a lengthy 10-K or 10-Q, identify notable changes in guidance or governance reported in 8-Ks, and navigate directly to sections that matter most for understanding Castle Biosciences’ molecular diagnostics business.
Castle Biosciences, Inc. (CSTL) – Form 144 overview
The filing reports a proposed sale of 16,932 common shares by insider-related entities, to be executed through Goldman Sachs & Co. LLC around 27 June 2025. At the most recent share count disclosed in the notice (28,872,315 shares outstanding), the planned disposition represents roughly 0.06 % of total shares, indicating a limited potential impact on the public float.
Historical sales disclosed for the preceding three months total 11,288 shares spread across multiple Maetzold family trusts, yielding aggregate gross proceeds of approximately $226,000 (sum of line-item figures). No additional company financial metrics, earnings data, or operational updates are provided in this Form 144.
Key takeaways for investors
- The filing signals continual, but small-scale, insider selling activity.
- Because the quantity is less than 0.1 % of shares outstanding, market impact is expected to be minimal under normal trading volumes.
- No mention is made of a Rule 10b5-1 trading plan; however, the signee affirms lack of undisclosed material adverse information as required by Rule 144.
Overall, the notice is routine and does not, on its own, imply any change in Castle Biosciences’ fundamentals or forward outlook.